PTO/SB/08A (10/01) (modified)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute fo	r form 1449A	/PTO \	TRADEM!		App	lication Numb r	10/663,061				
INFO			TRADEM	eude Cude	Filin	g Date	S ptember 12, 2003 Charl s N. S rhan				
_			DISCLOS		First	Named Inventor					
			APPLI		Art l	Jnit					
(L	ise as many	sheets	as necessal	ry)	Exar	Examiner Name					
Sheet	1	of	5		Atto	Attorney Docket Number 7213.13					
Sileet	'	101	1								
	<u> </u>			U.S. PAT	ENT	DOCUMENTS		Pages, Colur	nne line		
*Examiner Cite Initiats No.	DOCUMENT NUMBER Number - Kind Code (if known)			Publication Date MM-DD-YYYY		Name of Patente Applicant of Cited Do		or Where Relevant		t Passages or	
12	US- 4,	US- 4,666,701				Horrobin et al.					
1	US- 5,409,955			4/25/1995		Bockow et al.					
	US- 5,	US- 5,411,988			_	Bockow et al.					
17/	US- 5,	US- 5,709,855				Bockow					
	US- 6,	-				Mease et al.					
	US- 4,	201,211	1	5/6/1980		Chandrasekaran et a	l.				
	US- 5,	814,599	9	9/29/1998		Mitragotri et al.			_		
	US- 5,	846,974	4	12/8/1998	8 Kallman et al.						
	US- 4,	810,424	4	3/7/1989		Gerwick, et al.					
	US-										
	US-				7				-		
	US-	_									
	US-										
	US-				-						
			F	OREIGN P	ATE	NT DOCUMENTS					
	1		DOCUMENT	4			Pages, Columns, Lines,		TRANSLATION		
*Examiner City Initial No.	Country Code:		er - Kind Code if known)	Publication [MM-DD-YY	Name of Fateritee of		Where Relevant Passages or Relevant Figures Appear		YES	NO	
11	WO	91/169	914	11/14/199	1						
1//	WO	98/46	588	10/22/199	В						
	JP .	51863	342	7/27/1993		Bunshiyou et al.			×		
4	XP	00218	34773		T						
	1										
//			,//								
			1/	0							
EXAMINE	R SIGNATUI	P lb	The M	Kays	>	DATE CONSIDERED	509	1/09	4	•	
*EXAMINE citation if n	R: Initial if	referen	ce considere	d, whether dered. Include	r not	citation is in conformand of this form with next cor	e with MPE	609. Draw to applicant.	line thr	ough	

OIPE		
DEC 2 2 2003 (3)	U.S. Patent and Trade	PTO/SB/0 mark Office; U.S. DEPARTME
	Applicati n Numb r	10/663.061

Substitu	te for fo	rm 1449A/	PTO	RADE MARK OF	Applicati n Numb r	10/663,061					
INE	ODI	AATI	N D	ISCLOSURE	Filing Date	Sept mber 12, 2002					
				APPLICANT	I FIRST NAMED INV. DTOT	Charles N. S rhan					
				as necessary)	Art Unit						
	luse	as many	3/10010		Examiner Name						
Sheet	2		of	5	Attorney Docket Number	7213.13					
	OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS										
*Examiner	Cite	ı			TAL LETTERS), title of the article (when erial, symposium, catalog, etc.), date, page		TRANS	LATION			
initials	No.			number(s), pub	lisher, city and/or country where published		YES	NO			
KL		PCT/US	601/051	196 International Sear	ch Report						
		XP-002	200246	6, 1993.	unctions of hydroxy - docosahex						
		E.M. Hil in the ba	l, et al. arnacle	"Identification and eg Balanus balanoides",	g hatching activity of monohydro Abstract, XP-002200247, 1992	xy fatty acid eicosanoids					
		L. De Montarby, et al. "Synthesis stereoselectives de metabolites hydroxyles d'acides gras polinsatures", Bulletin De La Societe Chimique de France, No. 3, pgs. 419-432, 1989.									
	2	M. Yamane, et al., "Docosahexaenoic/arachidonic acid ω-hydroxylation system and differentiation in the human clonic adenocarcinoma cell line, Caco-2", Cancer Letters, Vol. 122, pgs. 51-59, 1998.									
	7	T. Kato, et al., "Production of Hydroxy Unsaturated Fatty Acids Using Crude Lipoxygenase Obtained from Infected Rice Plants", Bull. Chem. Soc. Jpn. Vol. 69, pgs. 1663-1666, 1996.									
				"Proceedings of the A American Oil Chemist	AOCS Short Course on Polyunsa s' Society 1987.	aturated Fatty Acids and					
	7		M. Ligo et al., "Inhibitory effects of docosahexaenoic acid on colon carcinoma 26 metastasis to the lung", <i>Br. J. Cancer</i> , 1997, pgs. 650-655.								
	V		G.E. Billman et al., "Prevention of sudden cardiac death by dietary pure ω-3 polyunsaturated fatty acids in dogs", <i>Circulation 99</i> 1999, pgs. 2452-2457.								
	7				essentiality of an recommended J. Am. Coll. Nutr. 1999, pgs. 487						
		R. Marc after my	hioloi, ' ocardi	"Dietary supplementate al interction: results of	ion with n-3 polyunsaturated fatt the GISSI-Prevenzione trial", <i>La</i>	y acids and vitamin E ancet 1999, pgs. 447-455.	10				
1	EXAMINER SIGNATURE CONSIDERED OF ON										
*EXAM citation	*EXAMINER: Initial if reference considered, whether of not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.										

PTO/SB/08A (10/01) (modified) + U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE 10/663.061

Substitute for for	111111111111	RADEMARK OF	Application Number							
INFOR	AATION D		Filing Date	Sept mber 12, 2003						
		ISCLOSURE ARRIVED	First Named Inventor	Charles N. Serhan						
-		APPLICANT	Art Unit							
(use as many sheets as necessary) Examiner Name										
Sh et 3	of 5 Attorney Docket Number 7213.13									
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS										
Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue										
Initials No.	rem (number(s), publish	er, city and/or country where publishe	96(3), Voidine-15508 9d	YES	NO				
	G. Weissmann	, "Aspirin", <i>Sci. Am.</i> 199	1, pgs. 84-90.							
6	A ! Marcus "F	Platelets: their role in her	nostasis, thrombosis, and infla	ammation" Inflammation:						
X	Basic Principle	es and Clinical Correlates	; 1999, pgs. 77-95.							
	J. Claria et al., endothelial cel	"Aspirin triggers previou I-leukocyte interactions",	sly undescribed bioactive eico Proc. Natl. Acad. Sci. USA 19	sanoids by human 195, pgs. 9475-9479.						
	C.N. Serhan et al, "Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils", <i>Biochemistry</i> 1995, pgs. 14609-14615.									
	N. Chiang et al., "Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion", <i>J. Clin. Invest.</i> 1999, pgs. 309-316.									
	H.R. Herschman, "Recent progress in the cellular and molecular biology of prostaglandin synthesis", <i>Trends Cardiovasc. Med.</i> 1998, pgs. 145-150.									
	P. Needleman et al., "The discovery and function of COX-2", J. Rheumatol 1997, pgs. 6-8.									
	and murine pe	N. Chiang et al., "Aspirin-triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: Development of a specific 15-epi-LXA4 ELISA", J. Pharmacol. Exp. Ther. 1998, pgs. 779-790.								
	G. Xiao et al., aspirin-treated	"Analysis of hydroperoxi I human prostaglandin H	de-induced tyrosyl radicals an synthase-2", <i>Biochemistry</i> 19	d lipoxygenase activity in 97, pgs. 1836-1845.						
	eicosanoids",	K. Node et al., "Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids", Science 1999, pgs. 1276-1279.								
	S. Sethi et al., natural anti-fla	"Inhibition of phagocyte- primatory mechanism?"	endothelium interactions by o J. Dab. Clin. Med. 1996, pgs. 2	xidized fatty acids: A 27-38.						
EXAMINER S	IGNATURE	An Mar	DATE CONSIDERED	Sont 10°	1					
*EXAMINER: citation if not i	*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

PTO/SB/08A (10/01) (modified) U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	ute for form 1449A/PTO						Application Numb r	10/663,061			
INFORMATION DISCLOSURE					TE TR	A DEMARK	Filing Dat	Sept mb r 12, 2003	Sept mb r 12, 2003		
							First Named Inventor	Charl s N. S rhan			
STATEMENT BY APPLICANT							Art Unit				
	(us	e as n	nany s	sneet	s as neces	isary)	Examiner Name				
She t	T	4		of	5	· · · · · · · · · · · · · · · · · · ·	Attorney Docket Number	7213.13			
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS											
*Examiner	Cite			clude	name of the a	author (in CAPITAL	LETTERS), title of the article (when	appropriate), title of the	TRANSLATION		
initiais	No.			item	(book, maga	ızıne, joumai, senai number(s), publish	l, symposium, catalog, etc.), date, pa er, city and/or country where publishe	ge(s), volume-issue ed	YES	NO	
	1					lin H synthases 7, pgs. 234-247.	, nonsteriodal anti-inflammato	ry drugs, and colon			
					al., "Trans 9-144.	scellular regulat	ion of eicosanoid biosynthesi	s", Eicosanoid Protocols			
		ind Pu	luctibl <i>irit.</i> 19	e pro 96, p	staglandin gs. 19-26.	G/H synthase	tion and characterization of re from baculovirus-infected inse	ect cells", Protein Expres.			
1		cyt	J.H. Capdevila et al., "The highly stereoselective oxidation of polyunsaturated fatty acids by cytochrome P450BM-3", <i>J. Biol. Chem.</i> 1996, pgs. 22663-22671.								
		R). de _l	R.T. Ruettinger et al., "Epoxidation of unsaturated fatty acids by a soluble cytochrome P-45-dependent system from bacillus megaterium", <i>J. Biol. Chem.</i> 1981, pgs. 5728-5734.								
		eic	T.H. Lee et al., "Characterization and biologic properties of 5,12-dihydroxy derivatives of eicosapentaenoic acid, including leukotriene B5 and the double lipoxygenase product", J. Biol. Chem. 1984, pgs. 2383-2389.								
		C.I	C.N. Serhan et a;., "Nomenclature of lipoxins and related compounds dervived from arachidonic acid and eicosapentaenoic acid", <i>Prostaglandins</i> 1987, pgs. 201-204.								
			D.J. Hill et al., "Trout thrombocytes contain 12-but not 5-lipoxygenase activity", Biochim. Biophys. Acta 1999, pgs. 63-70.								
		glu en <i>Ac</i>	8.N. Cronstein et al., "A mechanism for the anti-inflammatory effects of corticosteriods: The glucocorticoid receptor regulates leukocyte adhesion to endotheliasl cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1", Proc. Natl. Acad. Sci. 1992, pgs. 9991-9995.								
		ch	T. Yokomizo et al., "A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis", <i>Nature</i> 1997, pgs. 620-624.								
1		the	e 12- a	and 1	5-lipoxyge	Regulation of einase monohyd nase monohyd nids 1998, pgs.	ndothelial cell and platelet rec rexides, 12-, 15-HETE and 13 339-346.	eptor-ligand binding by -HODE", <i>Prostaglandins</i>			
EXAMI	NER:	SIGNA	ATURI			ALTE	DATE CONSIDERED	SOT 19	V	./	
*EXAM	INER	: Initi	ial If	elerei	nce consid	ered whether	or not citation is in conforman	ce with MPEP 609. Draw	line th	rough	

PTO/SB/08A (10/01) (modified Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCI	+
Patent and Trademark Office, 0.5. DEPARTMENT OF COMMERCE	•

Substitute for form 1449A/PTO INFORMATION DISCLOSURE					Application Numb r	10/663,061				
				NECL OSLIBE	Filing Dat	S ptemb r 12, 2003				
					First Named Inventor	Charles N. Serhan				
1 21	STATEMENT BY APPLICANT (use as many sheets as necessary)				Art Unit					
	(U	oc as many	, ວາ ເ ປປ ເS	as necessary)	Examiner Name	3				
Sheet		5	of	5	Attorney Docket Number	7213.13				
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS										
*Examiner	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue									
Initials	No.			number(s), publish	er, city and/or country where publishe	ed	YES	NO		
1	1	P.M. R healthy	idker et / men",	al., "Inflammation, aspiri N. Engl. J. Med. 1997, po	n, and the risk of cardiovascul gs. 973-979.	ar disease in apparently				
		Comm	unicatio	n Relating to the Results	of the Partial International Se	arch				
	2	Takes	ni Teran	o, Ensho, Chemical Abst	ract 107:22439, pp. 63-71, 19	87.				
		Miller	Miller et al., Lipids, Chemical Abstract 112:117062, pp. 998-1003, 1989.							
	1	Hill, EN	Hill, EM. Proc R. Soc. London Ser. B., 247 (1318) pp 41-46, 1992.							
					·					
				In soll	<i>y</i>					
		SIGNATU	11	up May	S DATE CONSIDERED	Set /1	04			
	*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									

PTO/SB/08A (10/01) (modified)

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Substitute for form 1449A/PTO 10/663,061 Application Numb r **Filing Date** S ptember 12, 2003 INFORMATION DISCE Charles N. Serhan First Named Inv ntor STATEMENT BY APPLICANT **Art Unit** (use as many sheets as necessary) **Examiner Name** 1 of 1 Attorney Docket Number 7213.13 She t OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the TRANSLATION item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published YES NO Eritsland et al., "Effects of Highly Concentrated Omega-3 PUF As and Acetylsalicylic Acid: Alone and Combined, on Bleeding Time and Serum Liquid Profile", J, Olso City П *Hosp.*, Vol. 39 (8-9), pp. 97-101, 1989. lacovietto et al., "Modulation of Fibrinolytic Response to Venous Occlusion in Humans by a Combination of Low-Dose Aspirin and n-3 PUFAs", Arteriosclerosis Thrombosis, Vol. 10, pp. 1191-1197, 1992. Lau at al., "Effects of Fish Oil Supplementation on Non-Steroidal Anti-Inflammatory Drug (NSAID) Requirement in Patients with Mild Rheumatoid Arthritis - A Double-Blind Placebo Controlled Study", British Journal of Rheumatology, Vol. 32 (11), pp. 982-989. Rao et al, "Comparative Pharmacology of Cyclooxygenase Inhibitors on Platelet Function", Prostaglandins Leukot. Med., Vol. 18 (1), pp. 119-131, 1985 П П DATE CONSIDERED< EXAMINER SIGNATURE *EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.